Incyte to Host Webcast at 2010 ACR/ARHP Annual Scientific Meeting

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced that it has scheduled a webcast for 8:00 p.m. ET today, Wednesday, November 10, 2010 to review the INCB28050 Phase II results being presented today at 5:30 p.m. ET during the 2010 ACR/ARHP Annual Scientific Meeting in Atlanta.

The live webcast can be accessed by going to our website at under Investor Relations, Events and Webcasts. A replay of the webcast will also be available following the event.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology and inflammation. For additional information on Incyte, visit the Company's web site at


Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations & Corporate Communications

KEYWORDS:   United States  North America  Delaware  Georgia

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical



Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.